Blog: Phase 1 extension trial on CuATSM now enrolling in Australia | ALS Therapy Development Institute
Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model - ScienceDirect
Blog: Copper Compound (CuATSM) Shows Promise in ALS Lab Studies | ALS Therapy Development Institute
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits - ScienceDirect
Neuroprotective effect of CuATSM on neurotoxin-induced motor neuron loss in an ALS mouse model - ScienceDirect
64Cu-ATSM Positron Emission Tomography/Magnetic Resonance Imaging of Hypoxia in Human Atherosclerosis | Circulation: Cardiovascular Imaging
Relationship between 18 F-FDG SUV roi and 62 Cu-ATSM SUV roi obtained... | Download Scientific Diagram
Breakthrough in motor neurone disease research gives hope | Pursuit by The University of Melbourne
What's the story with CuATSM – ALS Society of Canada
Collaborative Medicinal Development Enrolls First Patient In a Randomized, Placebo-Controlled Clinical Trial of CuATSM For The Treatment of Amyotrophic Lateral Sclerosis
MND in the news - CuATSM (copper ATSM)
First ALS Patient Enrolled in Phase 2/3 Trial of CuATSM
CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background | Scientific Reports
CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background | Scientific Reports
PDF) CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background
Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy | PNAS
A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy - International Journal of Radiation Oncology, Biology, Physics
Summary for ALS Patients about CuATSM and Clinical Trials « Linus Pauling Institute Blog
CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease - Southon - 2020 - British Journal of Pharmacology - Wiley Online Library
New ALS drug slows disease progression in groundbreaking clinical trial
MND Australia - Latest news on copper-ATSM The first clinical trial of copper-ATSM as a potential treatment option for MND will start in 2016. Cu-ATSM therapy was developed in Australia, the first-in-man
Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease - Jakaria - 2021 - Journal of Neurochemistry - Wiley Online Library
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits - ScienceDirect
